Table 1 Characteristicsof CRAB-BSI patients with Tigecycline therapy and Cefoperazone/Sulbactam therapy
|  | Tigecycline therapy (n = 135) | Cefoperazone/Sulbactam therapy (n = 75) | P value |
|---|---|---|---|
Age (years) | 62 (21–95) | 60 (3–85) | 0.086 |
Male sex | 94 (69.6%) | 55 (73.3%) | 0.571 |
ICU admission | 101 (74.8%) | 55 (73.3%) | 0.814 |
APACHE II score | 20 (9–33) | 18 (7–31) | 0.063 |
APACHE II score < 20 | 66 (48.9%) | 48 (64%) |  |
APACHE II score ≥ 20 | 69 (51.1%) | 27 (36%) | 0.035 |
PBS | 3 (0–7) | 3 (0–8) | 0.098 |
CPIS | 7 (2–12) | 6 (2–10) | 0.006 |
28 day mortality | 70 (51.9%) | 22 (29.3%) | 0.001 |
APACHE II score < 20 | 30.3% (20/66) | 18.8%(9/48) | 0.118 |
APACHE II score ≥ 20 | 72.5% (50/69) | 48.1% (13/27) | 0.023 |
Underlying disease | |||
 hypertension | 58 (43.0%) | 23 (30.7%) | 0.053 |
 hepatitis/cirrhosis | 24 (17.8%) | 19 (25.3%) | 0.131 |
 diabetes | 22 (16.3%) | 12 (16.0%) | 0.560 |
 renal insufficiency | 23 (17.0%) | 11 (14.7%) | 0.406 |
 coronary | 17 (12.6%) | 9 (12%) | 0.544 |
 respiratory | 17 (12.6%) | 8 (10.7%) | 0.431 |
 tumor | 9 (6.7%) | 5 (6.7%) | 0.622 |
Comorbid conditions | |||
 pulmonary infection | 51 (37.8%) | 24 (32.0%) | 0.247 |
 septic shock | 41 (30.4%) | 5 (6.7%) | 0.000 |
 respiratory failure | 24 (17.8%) | 15 (20.0%) | 0.412 |
 MOF | 16 (11.9%) | 2 (2.7%) | 0.017 |
 abdominal cavity infection | 12 (8.9%) | 2 (2.7%) | 0.069 |
 stroke | 3 (2.2%) | 4 (5.3%) | 0.208 |
 gastrointestinal bleeding | 5 (6.7%) | 2 (2.7%) | 0.515 |